Axon Enterprise, Inc. (NASDAQ:AXON) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have been assigned an average rating of “Buy” from the fourteen analysts that are presently covering the stock, MarketBeat reports. Fourteen equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $542.15.

A number of brokerages have recently issued reports on AXON. Needham & Company LLC increased their target price on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Robert W. Baird increased their target price on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a research report on Friday, December 6th. JMP Securities increased their target price on Axon Enterprise from $610.00 to $725.00 and gave the company a “market outperform” rating in a research report on Tuesday, February 4th. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $500.00 to $700.00 in a research report on Tuesday, December 3rd. Finally, Northland Securities increased their target price on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research report on Monday, November 11th.

Axon Enterprise Trading Up 3.9 %

Axon Enterprise stock opened at $710.01 on Wednesday. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. Axon Enterprise has a 12 month low of $260.27 and a 12 month high of $715.99. The stock’s 50 day simple moving average is $625.48 and its two-hundred day simple moving average is $514.81. The firm has a market cap of $54.14 billion, a PE ratio of 183.47, a P/E/G ratio of 6.79 and a beta of 1.05.

Insiders Place Their Bets

In related news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $639.69, for a total transaction of $639,690.00. Following the completion of the sale, the director now directly owns 24,259 shares of the company’s stock, valued at approximately $15,518,239.71. This trade represents a 3.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jeffrey C. Kunins sold 2,304 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $654.79, for a total value of $1,508,636.16. Following the sale, the insider now directly owns 128,542 shares of the company’s stock, valued at $84,168,016.18. The trade was a 1.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,711 shares of company stock valued at $5,631,561 in the last three months. 6.10% of the stock is currently owned by insiders.

Institutional Trading of Axon Enterprise

A number of hedge funds and other institutional investors have recently modified their holdings of AXON. Bleakley Financial Group LLC increased its position in shares of Axon Enterprise by 7.9% during the 3rd quarter. Bleakley Financial Group LLC now owns 1,507 shares of the biotechnology company’s stock worth $602,000 after purchasing an additional 110 shares during the last quarter. Stratos Wealth Advisors LLC acquired a new stake in shares of Axon Enterprise during the 3rd quarter worth about $259,000. Blue Trust Inc. increased its position in shares of Axon Enterprise by 234.5% during the 3rd quarter. Blue Trust Inc. now owns 291 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 204 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Axon Enterprise by 7.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 75,201 shares of the biotechnology company’s stock worth $30,050,000 after purchasing an additional 5,218 shares during the last quarter. Finally, Toth Financial Advisory Corp grew its position in Axon Enterprise by 35.7% in the 3rd quarter. Toth Financial Advisory Corp now owns 475 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 125 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.